title: [Application of anti-VEGF agents in treatment of neovascular glaucoma and anti-scarring in filtering surgery].
abstract: Neovascular glaucoma (NVG) is a group of secondary glaucoma which led by a variety of diseases that have anoxia or ischemia to the retina. Some studies have found that the etiology was related to the vascular endothelial growth factor (VEGF). At present, anti-VEGF as a treatment method to NVG, has become an important advance in the field of glaucoma research, which established a new way to improve the prognosis. This review mainly focused on the pathophysiologic basis and clinical research of NVG, fundamental research and applications about four kinds of anti-VEGF agents (Bevacizumab, Ranibizumab, Pegaptanib and Aflibercept) and application of treatment of NVG and anti-scarring in filtering surgery. The review also provided references for the clinical treatment of NVG and improving the success rate of operation.
authors.affiliation: Department of Ophthalmology, The Second Xiangya Hospital of Central South University, Changsha 410011, China.
authors.forename: Xu
authors.initials: X
authors.lastname: Jia
authors.affiliation: Department of Ophthalmology, The Second Xiangya Hospital of Central South University, Changsha 410011, China; Email: duanxchu@126.com.
authors.forename: Xuanchu
authors.initials: X
authors.lastname: Duan
mesh_terms: D052157:Aptamers, Nucleotide / Q000627:therapeutic use; D000068258:Bevacizumab / Q000627:therapeutic use; D002921:Cicatrix / Q000517:prevention & control*; D018463:Filtering Surgery; D015355:Glaucoma, Neovascular / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007511:Ischemia; D000069579:Ranibizumab / Q000627:therapeutic use; D012171:Retinal Vessels; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D052157:Aptamers, Nucleotide; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib; D000068258:Bevacizumab; D000069579:Ranibizumab